Suppliers / Ferring Controlled Therapeutics

Ferring Controlled Therapeutics

United Kingdom 44 employees Updated 9 July 2026

Ferring Controlled Therapeutics is an API and finished-dose manufacturer based in United Kingdom. It appears in 8 regulatory filings across 6 regulators, without an active US DMF or CEP on file. Its filings concentrate with NPRA (MY), MINSA (CR) and JFDA (JO). Its GMP standing is certified by MHRA (UK), ANVISA (Brazil) and NCELS (KZ), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 30 May 2019 as VAI.

0
active US DMFs
0
valid CEPs
5
registered plants 1 with an FDA FEI number
8
filings across 6 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 30 May 2019 VAI US FDA
  • 30 October 2014 NAI US FDA
  • 13 December 2012 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
East Kilbride, United Arab Emirates Not on file
GLASGOW, United Kingdom Not on file
GLASGOW, United Kingdom Not on file
United Kingdom, United Kingdom 3002806756
Ambernath, India Not on file

What they file, and where

Molecule Regulators Docs
Mesalazine SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
NPRA (MY) 2 None
MINSA (CR) 2 None
JFDA (JO) 1 None
INVIMA (CO) 1 None
ARCSA (EC) 1 None
EDE (AE) 1 None
MHRA (UK) None 5
ANVISA (Brazil) None 3
NCELS (KZ) None 2
EMA None 1

Comparing suppliers?

Choose your molecules and target markets. Ferring Controlled Therapeutics comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 30 May 2019.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates